Entrepreneur and medical researcher Dr. Scott Rocklage has spent over 30 years helping to turn the ideas of physicians, researchers and scientists into medicines and therapies to help people suffering with a wide range of medical conditions. Read more: Scott Rocklage | Bloomberg
He has helped the drugs Omniscan, Cubicin and Teslascan gain Food and Drug Administration approval. Dr. Rocklage has also helped get clinical trials for several other drug candidates. Plus, his writings about cutting-edge scientific topics have appeared in many peer-reviewed medical journals. He also has dozens of U.S. patents.
Since 2003, Dr. Scott Rocklage has been working with the venture capital firm 5AM Ventures first as a venture partner, then as a managing partner. The company provides early-stage companies with funding to develop their products.
Before he joined 5AM Ventures, Dr. Rocklage had gained decades of experience in strategic leadership and healthcare management. He held executive leadership positions or board membership with Nycomed Salutar, Cubist Pharmaceuticals, Semprus, Mikana, Ilypsa, Novira, Catalytica, Relypsa, Achaogen, Pulmatrix, Epirus and several other biotech companies. Dr. Rocklage is also Cidara, Kinestral and Rennovia’s board chairman.
Dr. Scott Rocklage attended UC, Berkley where he graduated with a bachelor’s degree in chemistry. He then attended the Massachusetts Institute of Technology and got a PhD in chemistry. At MIT Dr. Rocklage did research in 2005 Nobel Prize winner for chemistry Richard R. Schrock’s laboratory.
Known for being well organized, skilled at prioritizing and for embracing measured risk-taking, Dr. Rocklage has been a perfect fit for 5AM Ventures.
His background doing cutting-edge research in emerging life science technologies and methodologies makes him a great resource for early stage companies helping them transform their ideas into medicines and medical breakthroughs.
Based in the 5AM Ventures office in Boston, Massachusetts, Dr. Rocklage works closely with the portfolio management team, entrepreneurs, the board of directors and scientists and researchers engaged in groundbreaking activities.
He’s excited about the progress being made in targeted cancer treatments that attack specific genotypes and mutations.
Dr. Scott Rocklage anticipates a number of very unique ways in which cancer care will extend, improve and protect patients’ lives in the near future.